Liraglutide
CGH-LiNASH
Novo Nordisk · Phase 3 · Status n/r · Enrollment 36
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Liraglutide | Obesity or overweight | n/r | 6 | n/r | n/r |
| Bariatric Surgery | Obesity or overweight | n/r | 6 | n/r | n/r |
| Diet modification and exercise | Obesity or overweight | n/r | 6 | n/r | n/r |